Todd Zynda
Cardiovascular Disease · Long Beach, CANPI 1669618393
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 106 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) at 35.4% of the total. 2025 is the largest year on record at $940, 4.0 times the $235 reported in 2019. That places this record below the midpoint for cardiovascular disease clinicians in CA, where the typical reported total is $2,142.
Across 106 payments — averaging $21.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$813
- Abiomed$349
- AstraZeneca$125
- Abbott$123
- Boston Scientific$114
- Amgen$98
- plus $671 from 15 others
Across 111 payments — averaging $3474.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$311K
- Novartis$75K
What the payments were for
- Food & beverage$2,27899%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 55 | $813 |
| Abiomed | 6 | $349 |
| AstraZeneca | 7 | $125 |
| Abbott | 4 | $123 |
| Boston Scientific | 4 | $114 |
| Amgen | 4 | $98 |
| E.r. Squibb & Sons, L.L.C. | 5 | $84 |
| Biotronik Inc. | 1 | $82 |
| Johnson & Johnson | 4 | $70 |
| Kestra Medical Technology Services, Inc. | 3 | $68 |
| Lantheus Medical Imaging, Inc. | 3 | $68 |
| Shockwave Medical, Inc | 1 | $64 |
| Heartflow, Inc. | 1 | $45 |
| Novartis | 1 | $31 |
| Edwards Lifesciences | 1 | $28 |
| Merck | 1 | $28 |
| GSK | 1 | $24 |
| Boehringer Ingelheim | 1 | $24 |
| Stryker | 1 | $21 |
| GE HealthCare | 1 | $19 |
| Medtronic | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$150
How this compares
$2,292 in reported general payments places this provider in the 50th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 76 | $77,369 |
| EntrestoSacubitril/Valsartan | 35 | $55,407 |
| FarxigaDapagliflozin Propanediol | 29 | $37,271 |
| JardianceEmpagliflozin | 28 | $35,646 |
| BrilintaTicagrelor | 34 | $23,164 |
| VascepaIcosapent Ethyl | 19 | $16,460 |
| Icosapent Ethyl | 15 | $3,951 |
| Metoprolol Succinate | 70 | $1,172 |
| Rosuvastatin Calcium | 30 | $440 |
| Atorvastatin Calcium | 46 | $429 |
| Ezetimibe | 12 | $363 |
| Losartan Potassium | 18 | $301 |
| Furosemide | 40 | $277 |
| Spironolactone | 31 | $271 |
| Amlodipine Besylate | 19 | $241 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $125 | $60,43563 claims |
| NovartisEntresto | $31 | $55,40735 claims |
| Boehringer IngelheimJardiance | $24 | $35,64628 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Long Beach
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
- Pam Taubla Jolla$1.2M
- Wilber SuStanford$1.1M
- Thomas SmithSacramento$942K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.